# Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial

> **NCT05146635** · NA · UNKNOWN · sponsor: **Mansoura University** · enrollment: 110 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Intravesical Bcg
- **DRUG:** Intravesical chemotherapy (epirubicin)

## Key facts

- **NCT ID:** NCT05146635
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146635, "Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05146635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*